Bayer’s Koenen: Decentralized Trials For Pivotal Studies Not 'Black Or White Scenario'
Executive Summary
A cross-section of biopharma experts including senior executives of Bayer, Boehringer Ingelheim and Accenture and US FDA Director at the India Office deliberate digitization and evolving trends in clinical research, including the potential of decentralized trials and metadata-driven automation.
You may also be interested in...
Considerations For Using Established Versus Novel Endpoints In Decentralized Trials
UK and US regulators explained why some established clinical endpoints are not suitable for use in decentralized trials, and discussed principles to guide the development of novel digital endpoints.
Xarelto Still Climbs As Bayer Touts Successor
Bayer's pharmaceuticals chief Stefan Oelrich says that sales of treatments in the areas of ophthalmology, women’s healthcare and radiology have risen sharply, recovering from the effects of the COVID-19 pandemic.
FDA Draft Guidance Paves Way For Collecting Clinical Study Data Via Digital Health Technologies
The US FDA released draft guidance on how device makers, investigators and other stakeholders can use digital health solutions to collect data from clinical study participants remotely. Comments are due to the agency by 22 March 2022.